Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02074982




Registration number
NCT02074982
Ethics application status
Date submitted
27/02/2014
Date registered
3/03/2014
Date last updated
21/07/2017

Titles & IDs
Public title
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
Scientific title
A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)
Secondary ID [1] 0 0
2013-003434-32
Secondary ID [2] 0 0
CAIN457A2317
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Plaque Type Psoriasis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - placebo secukinumab

Experimental: AIN457 300 mg - patients received AIN457 (secukinumab) 300 mg (two secukinumab 150 mg injections) s.c. (subcutaneously) once every week at weeks 0, 1,2,3, followed by monthly dosing starting at week 4 to week 48 inclusive

Active comparator: Ustekinumab - patients received ustekinumab 45/90 mg (weight depended, according to label) s.c. (subcutaneously) and/or placebo secukinumab injections once every week at weeks 0,1,2, and 3 followed by monthly dosing starting at week 4 to week 48 inclusive


Treatment: Drugs: placebo secukinumab
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Moderate to Severe Plaque Psoriasis Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 16
Timepoint [1] 0 0
Week 16
Secondary outcome [1] 0 0
Speed of Onset Based on the Percentage of Participents Achieving PASI 75 at Week 4
Timepoint [1] 0 0
Week 4
Secondary outcome [2] 0 0
Percentage of Participants With Moderate to Severe Plaque Psoriasis Who Achieved Psoriasis Area and Severity Index (PASI) 90 at Week 52
Timepoint [2] 0 0
Week 52

Eligibility
Key inclusion criteria
* patients with moderate to severe plaque type psoriasis for at least 6 months before randomization
* patients eligible for systemic therapy with inadequately controlled psoriasis
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* forms of sporiasis other than plaque type psoriasis
* previous exposure to secukinumab, ustekinumab, or other biologic drugs targeting (IL)-17A or IL-17RA

Other protocol-defined inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/02/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
29/06/2016
Sample size
Target
Accrual to date
Final
676
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Phillip
Recruitment hospital [2] 0 0
Novartis Investigative Site - Sydney
Recruitment hospital [3] 0 0
Novartis Investigative Site - Woolloongabba
Recruitment hospital [4] 0 0
Novartis Investigative Site - East Melbourne
Recruitment postcode(s) [1] 0 0
2606 - Phillip
Recruitment postcode(s) [2] 0 0
2010 - Sydney
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
3002 - East Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
Oregon
Country [15] 0 0
United States of America
State/province [15] 0 0
South Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Virginia
Country [18] 0 0
United States of America
State/province [18] 0 0
Washington
Country [19] 0 0
Austria
State/province [19] 0 0
Innsbruck
Country [20] 0 0
Austria
State/province [20] 0 0
Linz
Country [21] 0 0
Austria
State/province [21] 0 0
Vienna
Country [22] 0 0
Austria
State/province [22] 0 0
Wien
Country [23] 0 0
Belgium
State/province [23] 0 0
Gent
Country [24] 0 0
Belgium
State/province [24] 0 0
Liege
Country [25] 0 0
Belgium
State/province [25] 0 0
Namur
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Pleven
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Sofia
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Varna
Country [29] 0 0
Canada
State/province [29] 0 0
Ontario
Country [30] 0 0
Canada
State/province [30] 0 0
Quebec
Country [31] 0 0
Denmark
State/province [31] 0 0
Arhus C
Country [32] 0 0
Estonia
State/province [32] 0 0
Tallinn
Country [33] 0 0
Estonia
State/province [33] 0 0
Tartu
Country [34] 0 0
France
State/province [34] 0 0
Bordeaux
Country [35] 0 0
France
State/province [35] 0 0
Brest
Country [36] 0 0
France
State/province [36] 0 0
La Rochelle
Country [37] 0 0
France
State/province [37] 0 0
Martigues
Country [38] 0 0
France
State/province [38] 0 0
Nice Cedex 3
Country [39] 0 0
Germany
State/province [39] 0 0
Augsburg
Country [40] 0 0
Germany
State/province [40] 0 0
Bad Bentheim
Country [41] 0 0
Germany
State/province [41] 0 0
Berlin
Country [42] 0 0
Germany
State/province [42] 0 0
Bielefeld
Country [43] 0 0
Germany
State/province [43] 0 0
Bochum
Country [44] 0 0
Germany
State/province [44] 0 0
Darmstadt
Country [45] 0 0
Germany
State/province [45] 0 0
Dessau-Rosslau
Country [46] 0 0
Germany
State/province [46] 0 0
Dresden
Country [47] 0 0
Germany
State/province [47] 0 0
Erlangen
Country [48] 0 0
Germany
State/province [48] 0 0
Frankfurt
Country [49] 0 0
Germany
State/province [49] 0 0
Hamburg
Country [50] 0 0
Germany
State/province [50] 0 0
Kiel
Country [51] 0 0
Germany
State/province [51] 0 0
Lubeck
Country [52] 0 0
Germany
State/province [52] 0 0
Ludwigshafen
Country [53] 0 0
Germany
State/province [53] 0 0
Mainz
Country [54] 0 0
Germany
State/province [54] 0 0
Muenster
Country [55] 0 0
Germany
State/province [55] 0 0
Münster
Country [56] 0 0
Germany
State/province [56] 0 0
Pommelsbrunn
Country [57] 0 0
Greece
State/province [57] 0 0
GR
Country [58] 0 0
Hungary
State/province [58] 0 0
Budapest
Country [59] 0 0
Hungary
State/province [59] 0 0
Szeged
Country [60] 0 0
Israel
State/province [60] 0 0
Afula
Country [61] 0 0
Israel
State/province [61] 0 0
Petach Tikva
Country [62] 0 0
Israel
State/province [62] 0 0
Tel Aviv
Country [63] 0 0
Italy
State/province [63] 0 0
BO
Country [64] 0 0
Italy
State/province [64] 0 0
MO
Country [65] 0 0
Italy
State/province [65] 0 0
VR
Country [66] 0 0
Korea, Republic of
State/province [66] 0 0
Korea
Country [67] 0 0
Korea, Republic of
State/province [67] 0 0
Gwangju
Country [68] 0 0
Netherlands
State/province [68] 0 0
CK
Country [69] 0 0
Netherlands
State/province [69] 0 0
Nijmegen
Country [70] 0 0
Netherlands
State/province [70] 0 0
Rotterdam
Country [71] 0 0
Netherlands
State/province [71] 0 0
Sneek
Country [72] 0 0
Netherlands
State/province [72] 0 0
Zwijndrecht
Country [73] 0 0
Norway
State/province [73] 0 0
Bergen
Country [74] 0 0
Portugal
State/province [74] 0 0
Coimbra
Country [75] 0 0
Portugal
State/province [75] 0 0
Lisboa
Country [76] 0 0
Portugal
State/province [76] 0 0
Lisbon
Country [77] 0 0
Portugal
State/province [77] 0 0
Porto
Country [78] 0 0
Slovakia
State/province [78] 0 0
Slovak Republic
Country [79] 0 0
Slovakia
State/province [79] 0 0
Slovak republic
Country [80] 0 0
Slovakia
State/province [80] 0 0
Bojnice
Country [81] 0 0
Slovakia
State/province [81] 0 0
Kosice
Country [82] 0 0
Spain
State/province [82] 0 0
Andalucia
Country [83] 0 0
Spain
State/province [83] 0 0
Asturias
Country [84] 0 0
Spain
State/province [84] 0 0
Barcelona
Country [85] 0 0
Spain
State/province [85] 0 0
Catalunya
Country [86] 0 0
Spain
State/province [86] 0 0
Comunidad Valenciana
Country [87] 0 0
Spain
State/province [87] 0 0
Las Palmas de G.C
Country [88] 0 0
Spain
State/province [88] 0 0
Madrid
Country [89] 0 0
Spain
State/province [89] 0 0
Pais Vasco
Country [90] 0 0
Switzerland
State/province [90] 0 0
Lausanne
Country [91] 0 0
Taiwan
State/province [91] 0 0
Lin-Kou
Country [92] 0 0
Taiwan
State/province [92] 0 0
Taipei
Country [93] 0 0
Turkey
State/province [93] 0 0
Balcova / Izmir
Country [94] 0 0
Turkey
State/province [94] 0 0
Bursa
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Manchester
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Perthshire
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Surrey
Country [98] 0 0
United Kingdom
State/province [98] 0 0
West Yorkshire
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Coventry
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Harrogate
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Hull
Country [102] 0 0
United Kingdom
State/province [102] 0 0
Stoke-on-Trent

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
Trial website
https://clinicaltrials.gov/study/NCT02074982
Trial related presentations / publications
Alpalhao M, Duarte J, Diogo R, Vandemeulebroecke M, Ortmann CE, Kasparek T, Filipe P. Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region. BioDrugs. 2022 Nov;36(6):781-789. doi: 10.1007/s40259-022-00558-2. Epub 2022 Nov 5.
Merola JF, McInnes IB, Deodhar AA, Dey AK, Adamstein NH, Quebe-Fehling E, Aassi M, Peine M, Mehta NN. Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications. Rheumatol Ther. 2022 Jun;9(3):935-955. doi: 10.1007/s40744-022-00434-z. Epub 2022 Mar 19.
Conrad C, Ortmann CE, Vandemeulebroecke M, Kasparek T, Reich K. Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis. Dermatol Ther (Heidelb). 2022 Jan;12(1):233-241. doi: 10.1007/s13555-021-00654-1. Epub 2021 Dec 6.
Augustin M, Thaci D, Eyerich K, Pinter A, Radtke M, Lauffer F, Mrowietz U, Gerdes S, Pariser D, Lebwohl M, Sieder C, Melzer N, Reich K. Continued treatment with secukinumab is associated with high retention or regain of response. Br J Dermatol. 2020 Jan;182(1):67-75. doi: 10.1111/bjd.17991. Epub 2019 Jul 17.
Thaci D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015 Sep;73(3):400-9. doi: 10.1016/j.jaad.2015.05.013. Epub 2015 Jun 17.
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02074982